Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Jiangsu Recbio Technology / Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/jiangsu-recbio-technology-co-ltd-class-h">Jiangsu Recbio Technology</a> is a pre-revenue biotechnology company at a critical juncture, with its lead vaccine candidates for shingles (REC610) and HPV (REC603) advancing through late-stage clinical trials and regulatory review in China.</li>
 <li>The company's core technological strength lies in its novel adjuvant and protein engineering platforms, which have the potential to produce vaccines with improved efficacy and safety profiles compared to existing products.</li>
 <li>Significant financial and execution risks remain, as the company is currently loss-making and has faced delays in the submission of its marketing application for the HPV vaccine, a key potential value driver.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Jiangsu Recbio Technology is a pre-revenue biotechnology company at a critical juncture, with its lead vaccine candidates for shingles (REC610) and HPV (REC603) advancing through late-stage clinical trials and regulatory review in China.
  The company's core technological strength lies in its novel adjuvant and protein engineering platforms, which have the potential to produce vaccines with improved efficacy and safety profiles compared to existing products.
  Significant financial and execution risks remain, as the company is currently loss-making and has faced delays in the submission of its marketing application for the HPV vaccine, a key potential value driver.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Jiangsu Recbio Technology (2179 HK) - Aug 2026

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Beijing Health Guard Biotechnology / Equity Capital Markets

Beijing Health Guard Biotechnology (833575 CH)

<ul>
<li>The real market space of China’s HPV vaccines is much smaller-than-expected. Investment logic of vaccine companies is different from biotech - They either become large vaccine enterprises or are eliminated.</li>
<li>Low-Valent HPV vaccines would easily enter a price war or be included in National Immunization Program. 9-valent HPV vaccines would be the main battlefield, which is a highly competitive market.</li>
<li>Health Guard is facing increasing survival risks. Based on the concerns about the commercialization outlook of HPV vaccines, we’re not sure if the Company would bring expected returns to investors.</li>
</ul>


The real market space of China’s HPV vaccines is much smaller-than-expected. Investment logic of vaccine companies is different from biotech - They either become large vaccine enterprises or are eliminated.
Low-Valent HPV vaccines would easily enter a price war or be included in National Immunization Program. 9-valent HPV vaccines would be the main battlefield, which is a highly competitive market.
Health Guard is facing increasing survival risks. Based on the concerns about the commercialization outlook of HPV vaccines, we’re not sure if the Company would bring expected returns to investors.


Pre-IPO Beijing Health Guard Biotechnology - The Story of the HPV Vaccine Is Not as Good as Imagined

External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

<ul><li>9-Valent HPV Vaccine, REC603: The Ph III trial of REC603 in females aged 9-45, which recruited a total of 16,050 subjects, is in process.</li><li>Recbio has completed three doses vaccination of immune-bridging trial in younger age groups and the immunogenicity comparative trial with Gardasil®9.</li><li>The Company now follows up on the subjects of primary efficacy trial. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

9-Valent HPV Vaccine, REC603: The Ph III trial of REC603 in females aged 9-45, which recruited a total of 16,050 subjects, is in process.Recbio has completed three doses vaccination of immune-bridging trial in younger age groups and the immunogenicity comparative trial with Gardasil®9.The Company now follows up on the subjects of primary efficacy trial. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Recbio (2179 HK) – Clinical Development of Core Pipeline Products Continues

<ul><li>Recbio announced positive results in the Phase II study of its COVID vaccine ReCOV which compared the immunogenicity and safety to Pfizer’s mRNA vaccine, COMIRNATY®, as a booster vaccination.</li><li>The head-to-head trial enrolled 600 subjects with basic immunization of two doses of inactive vaccines in the Philippines and the results were upon 14 days post-booster.</li><li>Statistical superiority in immunogenicity vs. COMIRNATY® against both prototype strains and Omicron strains.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Recbio announced positive results in the Phase II study of its COVID vaccine ReCOV which compared the immunogenicity and safety to Pfizer’s mRNA vaccine, COMIRNATY®, as a booster vaccination.The head-to-head trial enrolled 600 subjects with basic immunization of two doses of inactive vaccines in the Philippines and the results were upon 14 days post-booster.Statistical superiority in immunogenicity vs. COMIRNATY® against both prototype strains and Omicron strains.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Recbio (2179 HK) – Superior immunogenicity on ReCOV vs. Pfizer’s mRNA vaccine

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Lygend Resources & Technology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lygend-resources-technology" target="_blank" data-smartkarma-citation="entities:36493:1" rel="noopener">Lygend Resources &amp; Technology (2245 HK)</a> raised US$470m in its Hong Kong IPO.</li>
<li>Lygend Resources &amp; Technology (Lygend) is a nickel trading and production firm with a portfolio covering multiple areas across the nickel industry value chain.</li>
<li>In this note we will talk about the trading dynamics.</li>
</ul>



Lygend Resources &amp; Technology (2245 HK) raised US$470m in its Hong Kong IPO.
Lygend Resources &amp; Technology (Lygend) is a nickel trading and production firm with a portfolio covering multiple areas across the nickel industry value chain.
In this note we will talk about the trading dynamics.


Lygend Resources & Technology IPO Trading - Tepid Subscription but Potential Upside Remains

China

Jiangsu Recbio Technology is an innovative vaccine company dedicated to the research, development, production, and commercialization of recombinant protein vaccines and related adjuvant technologies. Its pipeline includes vaccines for cervical cancer, shingles, COVID-19, influenza, and tuberculosis. The company was founded in 2012 and is headquartered in Taizhou, Jiangsu, PRC.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jiangsu Recbio Technology (2179 HK)

Primer: Jiangsu Recbio Technology (2179 HK) - Aug 2026

Jiangsu Recbio Technology is a pre-revenue biotechnology company at a critical juncture, with its lead vaccine candidates for shingles (REC610)...

αSK Primers

Pre-IPO Beijing Health Guard Biotechnology - The Story of the HPV Vaccine Is Not as Good as Imagined

The real China’s HPV vaccine market could be smaller-than-expected.After being included in National Immunization Program, vaccine business will be...

Xinyao (Criss) Wang

Recbio (2179 HK) – Clinical Development of Core Pipeline Products Continues

9-Valent HPV Vaccine, REC603: The Ph III trial of REC603 in females aged 9-45, which recruited a total of 16,050 subjects, is in process.

CMB International

Recbio (2179 HK) – Superior immunogenicity on ReCOV vs. Pfizer’s mRNA vaccine

Recbio announced positive results in the Phase II study of its COVID vaccine ReCOV which compared the immunogenicity and safety to Pfizer’s mRNA...

CMB International

Lygend Resources & Technology IPO Trading - Tepid Subscription but Potential Upside Remains

Lygend Resources & Technology (2245 HK) raised US$470m in its Hong Kong IPO. In this note we will talk about the trading dynamics.

Clarence Chu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)